AlphAIAlphAI — Financial news for AI agents
investing.comSEP 153 min read$KMTS

Kestra Medical earnings analysis: questions answered and next catalysts

Kestra Medical Technologies (KMTS) reported Q1 FY2027 revenue of $31.0M, beating estimates and raising FY2027 guidance to $141M. Gross margin improved to 56.5%, but EPS missed by 66.7%. Management expects mid-70% gross margin in 2–3 years. Next catalysts include late-stage R&D updates and Q2 earnings. Analysts maintain a Strong Buy rating with $30 price targets.

Original reporting
investing.com
Published Sep 15, 2026, 6:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KMTS
Neutral
high confidence
Mentioned
$KMTS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KMTSNeutralHigh
01

Why it matters

The earnings release provides fresh guidance and financing details, shifting the risk/reward profile.

02

Market read

Earnings beat and guidance raise create short-term trading opportunities; EPS miss and cash burn add caution.

03

What to watch

Potential regulatory scrutiny on WCD market and competitive pressure from ZOLL.

Relevance 8/10Novelty 8/10Timing: after-hours Sep 14 and early Sep 15

Background

Kestra Medical Technologies (KMTS) is a small-cap medical device company focused on wearable cardiac defibrillators.

Company-level read

Ticker impact

$KMTSNeutralHigh confidence
Context

Kestra Medical reported Q1 FY27 results with 60% revenue growth, raised FY2027 guidance, and disclosed a $200M term loan, all for the first time.

Expected impact

Potential short-term rally if guidance holds, but volatility expected on operating expense concerns.

Evidence & confidence

Guidance lift and new financing are material new facts; EPS miss tempers enthusiasm.

Market effects

Sector

Positive for wearable cardiac devices sector as Kestra's growth may lift peers.

Regional

U.S. biotech/medical device stocks could see modest gains.

Global

Limited to U.S. small-cap medical technology space.

Counterpoint

What could challenge this read

High cash burn and widening EPS loss could lead to a sell-off despite revenue beat.

Key entities

  • company
    Kestra Medical Technologies

    Issuer of the earnings report.

  • competitor
    ZOLL

    Competing WCD provider mentioned as a competitive risk.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min
SEP 14
$KMTSHigh

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS): Results of Operations and Financial Condition

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported

SEC EDGAR 8-K2 min
JUL 16
$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

yahoo.com6 min
JUL 15
$KMTSMed

Kestra Secures $200M Non-Dilutive Financial To Strengthen Balance Sheet And Fuel Growth

Kestra Medical Technologies (KMTS) said it secured a five-year, up to $200M non-dilutive term loan facility managed by Pharmakon Advisors. A $75M tranche closed, retiring part of its $45M loan and covering fees. Remaining tranches total $125M with revenue and acquisition conditions. The loan has 48 months interest-only at 3-month SOFR plus 5.5% (3.25% floor).

rttnews.com4 min
JUL 15
$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

yahoo.com4 min